Healthcare · Medical - Devices
Price
$2.45
Market Cap
$3.4M
Employees
30
Beta
2.33
Avg Volume
297,388
CEO
Steven Shum
Business Description
INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was established on January 5, 2007, and its operations are based in Sarasota, Florida.
Business History
Price Overview
Last updated: Jun 27, 2026 7:59am (just now)$2.45
+1.21 (+97.58%)
Day Range
$1.81 – $3.08
52-Week Range
$1.20 – $169.60
50-Day MA
$1.71
200-Day MA
$10.34
Volume
114,274,519.00
Analyst Price Targets
Low
$20.00
Consensus
$20.00
High
$20.00
(1 analysts)
Share Structure
Outstanding
1,392,220.00
Float
1,385,711.00
Free Float
99.5%
High free float
— 99.5% of shares trade freely, ~0.5% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Small absolute float (1.4M shares) — even with a decent free float %, volume can be thin. Check average daily volume before sizing a position.
Price History (1 Year)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
| Period | Revenue | Net Income | Net Margin | YoY/QoQ |
|---|
Key Metrics
API Direct from provider
CALC Derived from statements
P/E Ratio (Price per dollar of earnings)
CALCStock Price / EPS (Diluted)
-0.01
Stock Price: $2.45
EPS (Diluted): -214.64
EPS (Diluted): -214.64
P/B Ratio (Price vs net asset value)
APIStock Price / Book Value Per Share
0.06
Stock Price: $2.45
Total Equity: $7.22M
Shares: 117,083
Total Equity: $7.22M
Shares: 117,083
EV/EBITDA (Total value vs operating profit)
APIEnterprise Value / EBITDA
-0.32
Market Cap: $3.41M
Total Debt: $2.02M
Cash: $2.08M
EBITDA: -$3.51M
Total Debt: $2.02M
Cash: $2.08M
EBITDA: -$3.51M
Enterprise Value (Takeover price (cap + debt - cash))
APIMarket Cap + Total Debt - Cash
$1.8M
Market Cap: $3.41M
Total Debt: $2.02M
Cash: $2.08M
Total Debt: $2.02M
Cash: $2.08M
P/S Ratio (Price per dollar of revenue)
APIStock Price / Revenue Per Share
0.06
Stock Price: $2.45
Revenue: $6.84M
Shares: 117,083
Revenue: $6.84M
Shares: 117,083
EV/Sales (Total value vs revenue — works when P/E can't)
API0.26
Gross Margin (Revenue left after direct costs)
APIGross Profit / Revenue
37.0%
Gross Profit: $2.53M
Revenue: $6.84M
Revenue: $6.84M
Operating Margin (Revenue left after all operations)
APIOperating Income / Revenue
-85.4%
Operating Income: -$5.84M
Revenue: $6.84M
Revenue: $6.84M
Net Margin (Revenue left as actual profit)
APINet Income / Revenue
-340.9%
Net Income: -$23.32M
Revenue: $6.84M
Revenue: $6.84M
ROE (Profit from shareholder equity)
APINet Income / Total Equity
-149.2%
Net Income: -$23.32M
Total Equity: $7.22M
Total Equity: $7.22M
ROIC (Profit from all invested capital)
APINOPAT / Invested Capital
-31.0%
Operating Income: -$5.84M
Tax Rate: 2.7%
Equity: $7.22M
Total Debt: $2.02M
Cash: $2.08M
Tax Rate: 2.7%
Equity: $7.22M
Total Debt: $2.02M
Cash: $2.08M
Current Ratio (Can it pay short-term bills)
APICurrent Assets / Current Liabilities
0.27
Current Assets: $2.76M
Current Liabilities: $10.33M
Current Liabilities: $10.33M
Debt/Equity (Leverage — debt vs equity)
CALCTotal Debt / Total Equity
0.28
Short-Term Debt: $1.27M
Long-Term Debt: $744,725
Total Debt: $2.02M
Total Equity: $7.22M
Long-Term Debt: $744,725
Total Debt: $2.02M
Total Equity: $7.22M
Rev/Share (Top-line per share)
CALCRevenue / Shares Outstanding
$58.43
Revenue: $6.84M
Shares: 117,083
Shares: 117,083
Book Value/Share (Net assets per share)
CALC(Total Assets - Total Liabilities) / Shares
$61.70
Total Equity: $7.22M
Shares: 117,083
Shares: 117,083
FCF/Share (Real cash generated per share)
CALC(Operating Cash Flow + CapEx) / Shares
$-60.28
Operating CF: -$7.01M
CapEx: -$43,412
Shares: 117,083
CapEx: -$43,412
Shares: 117,083
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
APILast Annual Dividend / Stock Price
0.0%
Last Dividend: N/A
Stock Price: $2.45
Stock Price: $2.45
Payout Ratio (Earnings paid out as dividends)
Dividends Paid / Net Income
—
Dividends Paid: N/A
Net Income: -$23.32M
Net Income: -$23.32M
Dividends paid not available in cash flow statement
Industry Benchmarks
Compares IVF against LLM-researched typical ranges for its
industry. One research call per industry, cached indefinitely — every stock in the same industry
reuses the same baseline.
Deep Analysis
Pre-flight intelligence scans the company first, then routes to the right analytical methods.
0
Company Classification
— What type of company is this?
1
Industry Landscape
— Where is the industry headed?
2
Company Momentum
— Where is this company trending?
3
Forward Projection
— 1Y & 2Y projected metrics (requires Layer 1 + 2)
4a
DCF Valuation
— Present value of future cash flows
4b
Earnings Power Value
— Floor value — worth with zero growth
4c
Anchored PE
— Industry PE adjusted for growth differential
4d
Reverse DCF
— What growth is the market pricing in?
4e
Revenue-Based DCF
— For growth/narrative companies (skip if mature earner)
4f
Anchored P/S
— Price-to-Sales peer comparison (skip if mature earner)
4g
Scenario Analysis
— Bull / Base / Bear (skip if mature earner)
4h
Dividend Discount Model
— For dividend/income stocks only
4i
Book Value Analysis
— For deep value / turnaround stocks only
4j
Insider Activity
— Are insiders buying or selling?
4f
Cash Flow Quality
— How trustworthy is the FCF?
4g
Debt Maturity Risk
— Can it handle its debt?
4h
Macro Environment
— Rates, market valuation, volatility
4i
Sector Intelligence
— How does this company compare within its sector?
4j
Revenue Confidence
— How reliable is the growth projection?
4k
Sensitivity Analysis
— How fragile is the fair value estimate?
4l
Sector Demand Cycle
— Is the sector in a boom, steady state, or contraction?
5
AI Investigation
— Adaptive research engine (Claude)
5b
Thesis Evaluation
— What does the market believe? (narrative/platform stocks only)
6
Valuation Synthesis
— Weighted verdict from all methods (requires Layer 4)
Income Statement (Annual)
Last updated: Jun 27, 2026 1:42am (6h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $4.2M | $822,196 | $3.0M | $6.5M | $6.8M |
| Cost of Revenue | $145,052 | $850,770 | $1.9M | $3.7M | $4.3M |
| Gross Profit | $4.0M | $-28,574 | $1.1M | $2.9M | $2.5M |
| Operating Expenses | $9.2M | $10.6M | $7.7M | $11.0M | $8.4M |
| Operating Income | -$5.2M | -$10.6M | -$6.8M | -$8.1M | -$5.8M |
| Net Income | -$6.7M | -$10.9M | -$8.0M | -$9.1M | -$23.3M |
| EBITDA | -$5.2M | -$10.8M | -$6.9M | -$7.1M | -$3.5M |
| EPS | $-1,099.64 | $-1,570.91 | $-489.96 | $-219.56 | $-214.64 |
| EPS (Diluted) | — | — | — | — | — |
Balance Sheet (Annual)
Last updated: Jun 27, 2026 1:42am (6h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | $5.7M | $90,135 | $232,424 | $741,396 | $2.1M |
| Total Current Assets | $6.3M | $621,087 | $1.3M | $1.3M | $2.8M |
| Total Assets | $10.5M | $3.7M | $18.5M | $46.4M | $20.2M |
| Current Liabilities | $1.3M | $3.3M | $8.0M | $17.9M | $10.3M |
| Long-Term Debt | $0 | $0 | $1.3M | $1.1M | $744,725 |
| Total Liabilities | $3.2M | $4.7M | $17.6M | $33.7M | $13.0M |
| Total Equity | $7.3M | $-977,612 | $892,825 | $12.7M | $7.2M |
| Retained Earnings | -$38.9M | -$49.8M | -$57.8M | -$67.2M | -$91.4M |
Cash Flow (Annual)
Last updated: Jun 27, 2026 1:42am (6h ago)| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$6.0M | -$6.6M | -$4.8M | -$3.0M | -$7.0M |
| Capital Expenditure | $-454,649 | $-12,728 | $-444,722 | $-183,703 | $-43,412 |
| Free Cash Flow | -$6.5M | -$6.6M | -$5.2M | -$3.2M | -$7.1M |
| Acquisitions (net) | -$1.7M | $-68,489 | -$2.1M | $472,008 | -$2.7M |
| Debt Repayment | — | — | — | — | — |
| Dividends Paid | — | — | — | — | — |
| Stock Buybacks | $0 | $0 | $0 | $0 | -$4.0M |
| Net Change in Cash | -$4.4M | -$5.6M | $142,289 | $508,972 | $1.3M |
Analyst Estimates (Annual)
Last updated: Jun 27, 2026 1:42am (6h ago)| Metric | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|
| Revenue |
$16.5M $16.5M – $16.5M
|
$26.0M $26.0M – $26.0M
|
$39.0M $39.0M – $39.0M
|
$52.7M $52.7M – $52.7M
|
| EBITDA |
-$14.9M -$14.9M – -$14.9M
|
-$23.5M -$23.5M – -$23.5M
|
-$35.2M -$35.2M – -$35.2M
|
-$47.5M -$47.5M – -$47.5M
|
| Net Income |
$-117,084 $-117,084 – $-117,084
|
$40,979 $40,979 – $40,979
|
$146,355 $146,355 – $146,355
|
$251,730 $251,730 – $251,730
|
| EPS | — | — | — | — |
Growth Trends (YoY %)
Last updated: Jun 27, 2026 1:42am (6h ago)| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue Growth | -80.2% | +267.4% | +116.3% | +4.7% |
| Gross Profit Growth | -100.7% | +3,901.1% | +164.6% | -12.0% |
| Operating Income Growth | -103.7% | +36.3% | -20.1% | +28.1% |
| Net Income Growth | -63.7% | +26.2% | -13.2% | -156.4% |
| EBITDA Growth | -106.0% | +36.0% | -3.8% | +50.9% |
Insider Trading (Recent)
Type codes
PPurchase
SSale
AAward / grant
MOption exercise
FIn-kind (tax)
CConversion
GGift
DReturn to issuer
All SEC Form 4 codes
Open market
- P Purchase
- Open-market or private purchase of shares.
- S Sale
- Open-market or private sale of shares.
Compensation (Rule 16b-3)
- A Award / grant
- Grant or award of securities (RSUs, options, etc.) under Rule 16b-3.
- D Return to issuer
- Securities disposed back to the company under Rule 16b-3.
- F In-kind (tax)
- Shares withheld or delivered to pay the option-exercise price or tax — not an open-market sale.
- I Discretionary
- Discretionary transaction under an employee plan — Rule 16b-3(f).
- M Option exercise
- Exercise or conversion of a derivative (option/RSU) into shares — exempt.
Derivatives
- C Conversion
- Conversion of a derivative security into the underlying shares.
- E Short expiration
- Expiration of a short derivative position.
- H Long expiration
- Expiration or cancellation of a long derivative position with value received.
- O OTM exercise
- Exercise of an out-of-the-money derivative.
- X ITM exercise
- Exercise of an in-the-money or at-the-money derivative.
Other exempt
- G Gift
- Bona fide gift of securities.
- L Small acquisition
- Small acquisition under Rule 16a-6.
- W Inheritance
- Acquisition or disposition by will or the laws of descent.
- Z Voting trust
- Deposit into or withdrawal from a voting trust.
Other
- J Other
- Other acquisition or disposition (explained in a Form 4 footnote).
- K Equity swap
- Transaction in an equity swap or similar instrument.
- U Tender / buyout
- Disposition via tender of shares in a change-of-control transaction.
Compensation-plan codes (A, D, F, M) are routine and rarely directional. Open-market P (buy) and S (sale) carry the most signal.
| Date | Insider | Type | Shares | Price | Value |
|---|---|---|---|---|---|
| 2025-12-30 | Krigsvold Terah Renee | 0.00 | $0.00 | $0 | |
| 2025-12-30 | Krigsvold Terah Renee | 4,375.00 | $8.96 | $39,200 | |
| 2022-12-29 | Krigsvold Terah Renee | 2.00 | $2,304.00 | $4,608 | |
| 2025-12-30 | Krigsvold Terah Renee | 11.00 | $2,119.68 | $23,316 | |
| 2023-01-13 | Krigsvold Terah Renee | 2.00 | $2,983.68 | $5,967 | |
| 2025-12-30 | Krigsvold Terah Renee | 3.00 | $17,280.00 | $51,840 | |
| 2023-01-31 | Krigsvold Terah Renee | 2.00 | $3,882.24 | $7,764 | |
| 2025-12-30 | Krigsvold Terah Renee | 3.00 | $17,683.20 | $53,050 | |
| 2025-12-03 | Szot Matthew K | S-Sale | 4.00 | $1.52 | $6 |
| 2025-12-04 | Szot Matthew K | J-Other | 3.00 | $0.00 | $0 |
| 2025-08-26 | Shum Steve | A-Award | 42,000.00 | $1.01 | $42,420 |
| 2025-08-26 | Szot Matthew K | A-Award | 45,000.00 | $1.01 | $45,450 |
| 2025-08-26 | Ryan Barbara | A-Award | 45,000.00 | $1.01 | $45,450 |
| 2025-08-26 | Goren Andrea | A-Award | 50,000.00 | $1.01 | $50,500 |
| 2025-08-26 | DAVIS TRENT D | A-Award | 45,000.00 | $1.01 | $45,450 |
| 2025-08-26 | Messina Rebecca | A-Award | 45,000.00 | $1.01 | $45,450 |
Narrative Economics
The story the market is telling about this stock — the intangible X-factor
(founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond
what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for IVF — it's generated by the pipeline (
market-narrative step).
No community reviews yet for IVF.
Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes
personal — only you see this
Sign in to save personal notes and rate your interest in this stock.
Data via Financial Modeling Prep · Cached for performance · fmp
v1.1.352 · d1100787 · 2026-06-26 11:39:30